Treace Medical Issues Preliminary Q4 Results, Highlights Growth

The latest announcement is out from Treace Medical Concepts ( (TMCI) ).

On January 13, 2026, Treace Medical Concepts reported preliminary, unaudited results showing fourth-quarter 2025 revenue of $62.1 million to $62.5 million, representing about a 9% year-over-year decline, while full-year 2025 revenue rose modestly by roughly 2% to a range of $212.3 million to $212.7 million, in line with its prior guidance. The company added approximately 202 new active surgeons in 2025 and ended the year with about 3,337 active surgeons, a 6% increase that now represents roughly one-third of the estimated 10,000 U.S. bunion surgeons, with management highlighting mid–single-digit growth in procedure volumes driven by adoption of its 3D bunion technologies despite macroeconomic and product-mix headwinds, and noting that formal 2026 financial guidance will be issued with its fourth-quarter 2025 earnings release in February 2026; executives emphasized maintaining Treace’s leading bunion-market position, further expanding procedure penetration and surgeon base, and improving profitability for shareholders as they present these trends to investors at the J.P. Morgan Healthcare Conference on January 14, 2026.

The most recent analyst rating on (TMCI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Treace Medical Concepts stock, see the TMCI Stock Forecast page.

Spark’s Take on TMCI Stock

According to Spark, TipRanks’ AI Analyst, TMCI is a Neutral.

Treace Medical Concepts faces significant financial challenges, with ongoing losses and negative cash flows being the most critical issues. The bearish technical indicators and negative valuation metrics further weigh down the stock’s attractiveness. However, recent corporate events provide some positive outlook for future financial flexibility and strategic growth.

To see Spark’s full report on TMCI stock, click here.

More about Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company focused on advancing the surgical management of bunions and related midfoot deformities, a condition affecting an estimated 67 million Americans, of whom about 1.1 million are annual surgical candidates. The company has pioneered and patented the Lapiplasty 3D Bunion Correction System, a suite of instruments, implants and surgical methods that correct the three-dimensional bunion deformity by stabilizing the unstable midfoot joint, and it also offers complementary systems such as Adductoplasty for midfoot correction, minimally invasive Nanoplasty and Percuplasty bunion solutions, the SpeedMTP fusion system, the SpeedPlate rapid compression implant platform, and IntelliGuide digital pre-operative planning technology aimed at expanding its presence in the bunion and foot and ankle surgery market.

Average Trading Volume: 838,346

Technical Sentiment Signal: Sell

Current Market Cap: $184.8M

For detailed information about TMCI stock, go to TipRanks’ Stock Analysis page.